BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 14.44 15.63 <NA> <unk> share with you
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 15.63 24.99 <NA> the story of one of my patients called celine celine is a housewife and lives in a rural district of cameroon in west central africa <unk>
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 25.85 35.37 <NA> <unk> six years ago at the time of her hiv diagnosis she was recruited to participate in the clinical trial which was running in her health district at the time 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 35.45 43.47 <NA> when i first met celine a little over a year ago <unk> she had gone for eighteen months without any antiretroviral therapy <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 43.04 45.42 <NA> and she was very ill 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 45.29 49.99 <NA> she told me that she stopped coming to the clinic when the trial ended
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 49.81 52.54 <NA> because she had no money for the bus fare
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 52.33 53.92 <NA> and was too ill to walk the
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 54.9 56.23 <NA> <unk> distance <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 56.04 62.3 <NA> now during the clinical trial she 'd been given all her antiretroviral drugs free of charge <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 62.3 66.85 <NA> and her transportation costs had been covered by the research funds <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 66.6 73.27 <NA> all of these ended once the trial was completed <unk> leaving celine with no alternatives <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 73.05 79.94 <NA> she was unable to tell me the names of the drugs she 'd received during the trial or even what the trial had been about
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 80.1 84.47 <NA> <unk> i didn 't bother to ask her what the results of the trial were
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 84.24 91 <NA> because it seemed obvious to me that she would have no clue <unk> yet what puzzled me most
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 90.78 100.58 <NA> was celine had given her informed consent to be a part of this trial <unk> yet she clearly did not understand the implications of being a participant
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 100.58 104.4 <NA> or what would happen to her once the trial had been completed
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 105.08 113.58 <NA> <unk> now i have shared this story with you as an example of what can happen to participants in the clinical trial when it is poorly conducted <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 113.39 121.32 <NA> maybe this particular trial yielded exciting results <unk> maybe it even got published in a high profile scientific journal <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 120.95 125.44 <NA> maybe it would inform clinicians around the world on how to improve on the
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 129.9 137.43 <NA> <unk> it would have done so at a price to hundreds of patients who like celine <unk> were left to their own devices
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 137.27 140.35 <NA> once the research had been completed <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 140.04 148.48 <NA> i do not stand here today to suggest in any way that conducting hiv clinical trials in developing countries is bad 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 148.11 154.94 <NA> on the contrary clinical trials are extremely useful tools <unk> and are much needed to address the burden of
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 154.87 164.03 <NA> <unk> disease in developing countries <unk> however <unk> the inequalities that exist between richer countries and developing countries in terms of funding
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 164.03 168.71 <NA> pose a real risk for exploitation especially in the context of <unk>
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 169.68 170.96 <NA> research 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 170.71 179.79 <NA> sadly enough the fact remains that a lot of the studies that are conducted in developing countries could never be authorized in the richer
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 179.75 184.59 <NA> <unk> countries which fund the research <unk> i 'm sure you must be asking yourselves
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 184.39 192.66 <NA> what makes developing countries especially those in sub saharan africa <unk> so attractive for these hiv clinical trials 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 192.38 198.97 <NA> well in order for a clinical trial to generate valid and widely applicable results 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 198.97 203.32 <NA> they need to be conducted with large numbers of study participants
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 203.1 204.97 <NA> and preferably on
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 204.96 209.29 <NA> <unk> population with a high incidence of new hiv infections <unk>
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 209.16 212.89 <NA> sub saharan africa largely fits this description 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 212.89 222.01 <NA> with twenty two million people living with hiv an estimated seventy percent of the thirty million people who are infected worldwide <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 221.85 224.93 <NA> also research within the continent
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 224.75 229.97 <NA> is a lot easier to conduct due to widespread poverty <unk> endemic diseases
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 230.07 238.16 <NA> and inadequate health care systems a clinical trial that is considered to be potentially beneficial to the population
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 237.96 246.38 <NA> is more likely to be authorized and in the absence of good health care systems <unk> almost any offer of medical assistance
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 246.38 254.97 <NA> is accepted as better than nothing even more problematic reasons include lower risk of litigation less rigorous
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 255.01 263.55 <NA> ethical reviews <unk> and populations that are willing to participate in almost any study that hints at a cure 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 263.75 265.26 <NA> as
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 265.01 273.4 <NA> funding for hiv research increases in developing countries and ethical review in richer countries become more strict 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 273.4 275.23 <NA> you can see why this context
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 276.42 282.46 <NA> <unk> very attractive the high prevalence of hiv drives researchers
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 282.03 287.61 <NA> to conduct research that is sometimes scientifically acceptable but on many levels
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 287.45 289.55 <NA> ethically questionable <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 289.55 299.17 <NA> how then can we ensure that in our search for the cure we do not take an unfair advantage of those who are already most affected by the pandemic <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 298.74 303.23 <NA> i invite you to consider four areas i think we can focus on
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 303.06 304.91 <NA> in order to improve the way in which
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 304.87 306.35 <NA> <unk> things are done <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 306.16 309.15 <NA> the first of these is informed consent 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 308.94 311.92 <NA> now in order for a clinical trial to be
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 311.93 320.61 <NA> considered ethically acceptable participants must be given the relevant information in a way in which they can understand 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 320.43 323.46 <NA> and must freely consent to participate
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 323.25 329.85 <NA> in the trial this is especially important in developing countries where a lot of participants consent to
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 329.81 330.82 <NA> <unk> research
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 330.49 336.57 <NA> because they believe it is the only way in which they can receive medical care or other benefits 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 336.2 344.59 <NA> consent procedures that are used in richer countries are often inappropriate or ineffective in a lot of developing countries 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 344.59 349.87 <NA> for example it is counterintuitive to have an illiterate study participant like
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 350.7 355.96 <NA> <unk> sign a lengthy consent form that they are unable to read let alone understand <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 355.68 367.12 <NA> local communities need to be more involved in establishing the criteria for recruiting participants in clinical trials as well as the incentives for participation <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 366.84 372.08 <NA> the information in these trials needs to be given to the potential participants
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 371.92 374.93 <NA> in linguistically and culturally acceptable
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 376.27 379.43 <NA> <unk> the second point i would like for you to consider
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 378.94 388.34 <NA> is the standard of care that is provided to participants within any clinical trial <unk> now this is subject to a lot of debate and controversy 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 387.88 394.62 <NA> should the control group in the clinical trial be given the best current treatment which is available
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 394.44 400.02 <NA> anywhere in the world or should they be given an alternative standard of care such
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 400 406.05 <NA> <unk> the best current treatment available in the country in which the research is being conducted 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 405.71 416.1 <NA> is it fair to evaluate a treatment regimen which may not be affordable or accessible to the study participants once the research has been completed <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 415.76 424.6 <NA> now in a situation where the best current treatment is inexpensive and simple to deliver <unk> the answer is straightforward <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 425.85 433.24 <NA> <unk> the best current treatment available anywhere in the world is often very difficult to provide in developing countries <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 432.84 437.09 <NA> it is important to assess the potential risks and benefits
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 436.67 443.68 <NA> of the standard of care which is to be provided to participants in any clinical trial <unk> and establish one
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 443.51 451.06 <NA> which is relevant for the context of the study and most beneficial for the participants within the study 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 450.63 454.73 <NA> that brings us to the third point i want you think about the
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 455.14 457.07 <NA> <unk> review of research 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 456.7 467.06 <NA> an effective system for reviewing the ethical suitability of clinical trials is primordial to safeguard participants within any clinical trial <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 466.63 469.29 <NA> unfortunately this is often
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 469.13 474.87 <NA> lacking or inefficient in a lot of developing countries <unk> local governments
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 476.18 484.62 <NA> <unk> set up effective systems for reviewing the ethical issues around the clinical trials which are authorized in different developing countries 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 484.62 490.78 <NA> and they need to do this by setting up ethical review committees that are independent of the government
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 490.62 496.96 <NA> and research sponsors <unk> public accountability needs to be promoted through transparency
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 496.72 499.84 <NA> and independent review by nongovernmental and
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 500 506.61 <NA> international organizations as appropriate <unk> the final point i would like for you to consider tonight
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 506.39 512.65 <NA> is what happens to participants in the clinical trial once the research has been completed <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 512.46 523.15 <NA> i think it is absolutely wrong for research to begin in the first place without a clear plan for what would happen to the participants once the trial has ended <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 522.99 529.97 <NA> now <unk> researchers need to make every effort to ensure that an intervention that has been shown
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 529.9 533.24 <NA> <unk> to be beneficial during a clinical trial
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 532.75 539.07 <NA> is accessible to the participants of the trial once the trial has been completed <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 539.07 546.57 <NA> in addition they should be able to consider the possibility of introducing and maintaining effective treatments
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 546.4 550.17 <NA> in the wider community once the trial ends <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 550.34 560.4 <NA> <unk> for any reason they feel that this might not be possible then i think they should have to ethically justify why the clinical trial should be conducted in the first place <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 560.21 570.07 <NA> now fortunately for celine <unk> our meeting did not end in my office <unk> i was able to get her enrolled into a free hiv treatment program
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 569.9 574.68 <NA> closer to her home <unk> and with a support group to help her cope 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 575.01 583.33 <NA> <unk> her story has a positive ending but there are thousands of others in similar situations who are much less fortunate <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 583.14 587.96 <NA> although she may not know this my encounter with celine
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 587.57 590.92 <NA> has completely changed the way in which i view
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 590.91 600.08 <NA> hiv clinical trials in developing countries and made me even more determined to be part of the movement to change the way in which things are done
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 600.67 605.15 <NA> <unk> i believe that every single person listening to me tonight
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 604.78 607.43 <NA> can be part of that change 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 607 614.67 <NA> if you are a researcher i hold you to a higher standard of moral conscience to remain ethical in your research 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 614.67 618.6 <NA> and not compromise human welfare in your search for answers <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 618.37 625.35 <NA> if you work for a funding agency or pharmaceutical company <unk> i challenge you to hold your employers
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 625.49 628.35 <NA> <unk> to fund research that is ethically sound 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 627.86 631.45 <NA> if you come from a developing country like myself <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 631.45 639.96 <NA> i urge you to hold your government to a more thorough review of the clinical trials which are authorized in your country <unk> 
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 639.59 647.59 <NA> yes there is a need for us to find a cure for hiv to find an effective vaccine for malaria to find
BoghumaKabisenTitanji_2012X 1 BoghumaKabisenTitanji_2012X 647.4 659.74 <NA> a diagnostic tool that works for t b but i believe that we owe it to those who willingly and selflessly consent to participate in these clinical trials to do this in a humane way
